Baidu
map

FIB-4指数:可预测慢乙肝患者抗病毒治疗后的肝癌风险

2021-04-12 MedSci原创 MedSci原创

FIB-4

FIB-4指数(Fibrosis 4 Score)?

这是一种无创性评估慢性肝病患者肝纤维化的一种方法,因为它不需要额外地做检查,只需要把体检单上的几个数值代入公式里计算即可。需要用到的数值包括年龄、ALT(谷丙转氨酶)、AST(天冬氨酸转氨酶)、PLT(血小板)。梅斯医学网站也提供了快捷的计算程序。见:慢性肝病患者肝纤维化FIB-4指数

FIB-4指数的计算公式为:     

FIB-4=年龄×AST/ PLT计数×√ALT

不同的肝病FIB-4指数评价的临界值略有不同。对于慢性乙型肝炎或丙型肝炎,FIB-4指数<1.45者无明显肝纤维化或只有2级以下的肝纤维化,与肝穿刺病毒学结果的符合率为94.7%;而FIB-4指数>3.25者的肝纤维化程度为3~4级或以上,与肝穿刺病毒学结果的符合率为82.1%。对于非酒精性脂肪肝,2级以下或3~4级以上的肝纤维化临界指分别为<1.3和>2.67。但也有研究认为,FIB-4指数对于排除明显肝纤维化更准确,优于对严重肝纤维化的诊断。在临床上,FIB-4指数对显著纤维化及肝硬化的预测效果优于APRI评分,在一定程度上可替代肝组织活检。

1、FIB-4指数可用于预测慢性乙型肝炎(CHB)患者发生HCC的风险

众所周知,发生肝细胞癌(HCC)是肝纤维化进展的结果,因此,早期确定进展期肝纤维化非常重要。韩国研究人员发表的一项研究表明,无创性的纤维化-4(FIB-4)指数[基于年龄、天门冬氨酸氨基转移酶(AST)、血小板计数(PLT)和丙氨酸氨基转移酶(ALT)水平]可用于预测慢性乙型肝炎(CHB)患者发生HCC的风险,优于AST和PLT比值指数(APRI)或谷氨酰转肽酶(GGT)和PLT比值(GPR)。

该项研究总共纳入444例接受肝活检和血清学肝纤维化标志物检测的CHB患者,对所有患者进行随访,监测HCC的发生,应用组织学纤维化分期作为参照,评估FIB-4、APRI和GPR对CHB患者的HCC风险的预测价值。

结果,组织学纤维化分期对5年和7年时HCC发生风险的预测价值最高[受试者工作特征曲线下面积(AUROC)分别为0.783和0.766],其次为FIB-4(预测5年和7年时HCC发生风险的AUROC分别为0.753和0.698)、APRI(预测5年和7年时HCC发生风险的AUROC分别为0.658和0.572)和GPR(预测5年和7年时HCC发生风险的AUROC分别为0.638和0.603)。

根据组织学纤维化分期(F4对比F0-3)和FIB-4指数(FIB-4 ≥ 3.25对比FIB-4 < 3.25)对患者进行风险分组,高风险组发生HCC的风险显著高于低风险组(P值分别为0.005和0.022)。

2、重复采样和计算FIB-4指数可以增加对未来肝硬化的预测

另一项研究表明,通过重复采样和计算FIB-4指数,而不是仅仅测量一次,可以增加对未来肝硬化的预测。研究人员使用了一个1985年至1996年之间非常庞大的实验室测试数据库,从多个采样场合获得了126942人的FIB-4的血液测试数据,以识别那些27年里发展为肝硬化的人。

结果显示,有40729人(32.1%)在5年内(平均间隔2.4年)进行了第二次测试。在随访期间共记录了581起严重肝病事件。所以,随着时间的推移FIB-4指数增加与严重肝病的风险有关;而重复FIB-4测试可帮助识别那些有严重肝病风险的人——两次测试里,FIB-4指数升高代表风险增加,下降代表风险降低。但是值得注意的是,据文献记载,成人FIB-4指数>3.6在诊断肝硬化中的特异性是87%,灵敏度是45%。也就是说,准确性仍然是该检查的一个问题,在该研究中,通过FIB-4指数可以识别出约50%的未来受肝硬化影响的

研究人员称,发展肝硬化需要很长时间。结果表明FIB-4指数可以识别出严重肝疾病的高风险人群和排除健康的人。通常以几年为间隔重新计算FIB-4指数就足够了。但是仍需要进一步改善该方法以减少产生假阳性结果的风险。

3、FIB-4指数可预知慢乙肝患者抗病毒治疗后的肝癌风险。

纤维化-4(FIB-4)指数可以评估慢性乙型肝炎(CHB)患者的肝纤维化程度,也是肝细胞癌(HCC)发生风险的预测因素,然而,对于长期接受核苷(酸)类似物(NA)治疗的无肝硬化的CHB患者,尚不清楚FIB-4值是否可以帮助确定其中HCC风险最低的患者。

我国台湾大学医学院、台湾大学医院Tseng等近日发表的一项研究表明,对于接受NA长期治疗的无肝硬化的CHB患者,治疗1年时的FIB-4值<1.30,结合性别为女性或PAGE-B(基于基线时的年龄、性别和血小板计数)评分较低,有助于确定HCC风险最低的患者。

该项回顾性多国研究总共纳入1936例不同种族、无肝硬化的CHB患者,所有患者均长期接受恩替卡韦或替诺福韦等NA治疗,探讨FIB-4的截点值1.30(表明轻度肝纤维化的截点值),是否可用于对这些患者的HCC风险进行分层。

结果,平均随访6.98年期间,总共48例患者发生HCC。治疗1年时的FIB-4值与HCC发生风险显著相关,对HCC发生风险的预测价值优于治疗前的FIB-4值。根据治疗1年时的FIB-4值是否超过1.30进行分层,高FIB-4组和低FIB-4组相比,患者的HCC风险显著增加(风险比:4.87,95%可信区间:2.48-9.55)。

多因素分析表明,患者性别和治疗1年时的FIB-4值为HCC发生风险的独立预测因素,治疗1年时FIB-4值较低的314例女性患者中,无一例发生HCC。

最后,对于PAGE-B评分较低的患者,结合治疗1年时的FIB-4值是否超过1.30,可以对HCC风险进行分层,PAGE-B评分<10、治疗1年时FIB-4值< 1.30患者的HCC发生风险最低,HCC年发生率仅为0.11%。

FIB-4在线使用:慢性肝病患者肝纤维化FIB-4指数

参考文献:

Kim MN, Lee JH, Chon YE, et al. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. Eur J Gastroenterol Hepatol. 2019 Sep 3.

Hannes Hagström, Mats Talbäck, Anna Andreasson, Göran Walldius, Niklas Hammar. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. Journal of Hepatology, 2020; DOI: 10.1016/j.jhep.2020.06.007

Tseng TC, Choi J, Nguyen MH, et al. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int. 2021 Feb;15(1):105-113.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-11-09 随行陆

    三人行

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-11-06 yufangchangjie

    学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-07-30 sjq027
  6. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-04-14 yahu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-04-14 lsndxfj
  9. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-04-14 lsndxfj
  10. [GetPortalCommentsPageByObjectIdResponse(id=1671784, encodeId=ec5d16e17843b, content=<a href='/topic/show?id=0bcc2342943' target=_blank style='color:#2F92EE;'>#乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23429, encryptionId=0bcc2342943, topicName=乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1826842253, createdName=sjzlzc016, createdTime=Thu Aug 26 14:30:45 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068648, encodeId=9cd61068648cc, content=三人行, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 17:24:30 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067544, encodeId=514e106e54439, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cb51507287, createdName=yufangchangjie, createdTime=Sat Nov 06 11:51:58 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032512, encodeId=ddf320325123e, content=<a href='/topic/show?id=1401534265f' target=_blank style='color:#2F92EE;'>#慢乙肝患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53426, encryptionId=1401534265f, topicName=慢乙肝患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Sun May 23 01:30:45 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062003, encodeId=4f10206200365, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Jul 30 21:30:45 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292543, encodeId=a454129254336, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292886, encodeId=6969129288655, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558422, encodeId=2d501558422e3, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564431, encodeId=f35d1564431d2, content=<a href='/topic/show?id=84cbe421d1' target=_blank style='color:#2F92EE;'>#FIB-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7421, encryptionId=84cbe421d1, topicName=FIB-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e814973101, createdName=lsndxfj, createdTime=Wed Apr 14 12:30:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956574, encodeId=e4369565e463, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/8061a962539d452bbfb306396ed79deb/e0ea950e3e474920b8d8d1b11a5ffced.jpg, createdBy=be095402886, createdName=ms5000000000121449, createdTime=Tue Apr 13 14:00:44 CST 2021, time=2021-04-13, status=1, ipAttribution=)]
    2021-04-13 ms5000000000121449

    学习了

    0

相关资讯

Clin Translational Gastroenterology:阿司匹林可以减少接受口服核苷类似物的慢性乙型肝炎患者的肝细胞癌发病率

肝细胞癌(HCC)是全球第二大癌症死亡的主要原因,全球每年诊断出的HCC病例超过500000例。

Dig Dis Sci: 甲胎蛋白水平是肝细胞癌患者根治性切除的重要指标

肝细胞癌(HCC)占所有肝癌类型的90%,是全球第五大最常见的癌症,也是与癌症相关的死亡的第三大主要原因。

GUT: 非酒精性脂肪肝患者发生肝外癌症的风险增加

非酒精性脂肪肝目前的发病率越来越高,有专家估计此病影响到约占世界人口的30%,NAFLD不仅限于严重的肝相关并发症(肝硬化,肝衰竭或肝细胞癌(HCC))。

World J Gastroenterology:化学栓塞术对肝细胞癌患者短期和长期预后的影响

原发性肝癌是目前最常见的恶性肿瘤之一,并且是全世界恶性肿瘤死亡和发病的前五位原因之一。肝细胞癌(HCC)是最常见的病理类型,约占所有原发性肝癌的90%。

Hepatology:肥胖和缺乏体力活动者患肝癌风险高!

肝细胞癌(HCC)仍然是癌症相关死亡的主要原因,肥胖者和缺乏体力活动与肝癌患病率相关!

Baidu
map
Baidu
map
Baidu
map